Expressão e função dos receptores para cininas em células de tumor de bexiga: mecanismos relacionados

• Autor(a) principal: Sgnaolin, Vanessa
• Data de Publicação: 2012
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Biblioteca Digital de Teses e Dissertações da PUC_RS
• Texto Completo: http://tede2.pucrs.br/tede2/handle/tede/1676
• topic: MEDICINA; FARMACOLOGIA MOLECULAR; BIOQUÍMICA; BEXIGA - DOENÇAS; NEOPLASIAS DA BEXIGA URINÁRIA; CININAS; CNPQ::CIENCIAS DA SAUDE::MEDICINA

This study was designed to characterize, by means of functional and molecular approaches, the relevance of kinin B1 and B2 receptors in bladder cancer. Our data clearly shows that both B1 des-Arg9-BK and B2 BK receptor agonists were able to stimulate the proliferation of the grade 3-derived bladder cancer T24 cells. Furthermore, the incubation of B1 and B2 receptor antagonists, SSR240612 and HOE140, respectively, markedly inhibited the proliferation rate of T24 cells. In contrast, only higher concentrations of BK elicited the proliferation of the grade 1 bladder cancer cell line RT4, while des-Arg9-BK incubation completely failed to induce its proliferation. Interestingly, real time PCR experiments revealed that mRNA expression of B2, and mainly B1 receptors was found superior in T24 cells, in comparison to the low malignity grade RT4 cells. Furthermore, data obtained using bladder cancer human biopsies revealed that B1 receptor expression was visibly increased in all tumoral samples or under chronic inflammation of bladder. Concerning the signaling pathways related to the mitogenic effects of kinins, we bring novel evidence showing that pharmacological inhibition of PI3Kg with AS252424 concentration-dependently reduced T24 cell proliferation induced by BK or des-Arg9-BK. Finally, the incubation of T24 cells with kinin agonists led to a marked activation of PI3K/AKT and ERK 1/2 signaling pathways, whereas p38 MAP kinase remained unaffected. Our results indicate that kinin B2, and especially B1 receptors appear to be implicated in bladder cancer progression. It is tempting to suggest that selective kinin antagonists might represent potential therapeutic alternatives for bladder cancer control.